Minireviews
Copyright ©The Author(s) 2019.
World J Nephrol. Aug 21, 2019; 8(4): 75-82
Published online Aug 21, 2019. doi: 10.5527/wjn.v8.i4.75
Table 1 Mycophenolic acid for induction treatment in antineutrophil cytoplasmic antibody-associated vasculitis
AuthorsYrStudy designNo PtDiagnosisANCAFollow-up in moRemission rate
Joy et al[6]2005Case series12WG: 7, MPA: 2, Renal Limited: 2; CS:1MPO: 3, PR3: 9126/10 - 60%
Koukoulaki et al[12]2006Case series22N/AN/A2418/22 – 81.8%
Stassen et al[15]2007Cohort32MPA: 3; WG: 29MPO: 3; PR3: 2948Complete remission: 25/32 - 78%; Partial remission: 6/32 - 19%
Hu et al[7]2008Randomized35N/AMPO: 28; PR3: 26Mycophenolate: 77.8% (14/18); CYC: 61.5% (8/13)
Silva et al[16]2010Cohort17MPA: 17MPO: 1718Remission at 6 mo: 13/17 - 76%; Sustained remission at 18 mo: 12/17 - 70%
Han et al[8]2011Randomized42N/AMPO: 426Mycophenolate: 78.9% (14/18); CYC: 63.6% (8/13)
Jones et al[9]2018Randomized140MPA: 49; GPA: 91MPO: 53; PR3: 8218Mycophenolate: 67% (47/70); CYC:61% (43/70)
Chen et al[17]2016Cohort34MPA: 34MPO: 348631/34 - 91.2%
Table 2 Mycophenolic acid for remission maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis
AuthorsYrStudy designNo PtDiagnosisANCAFollow-up in moRelapse rate
Nowack et al[10]1999Cohort11WG: 9; MPA: 2PR3: 9; MPO: 21/11 – 9% time to relapse 14 mo
Langford et al[11]2004Cohort14WGcANCA: 13; pANCA: 1Median 18 (range 1-50)6/14 - 43% median time to relapse 10 mo
Koukoulaki et al[12]2006Case series29N/AN/A2414/29 – 48.3%
Stassen et al[15]2007Cohort32WG: 29; MPA: 3PR3: 29; MPO: 348Median time to relapse: 16 mo; Relapse free survival 1-yr: 63%, 3-yr: 38%, 5-yr: 27%
Iatrou et al[13]2009Cohort22MPA: 16; WG: 4, RENAL LIMITED: 1; CSS: 1MPO: 18; PR3: 4186/19 - 31.58% - median time to relapse 21.5 mo (range 18-60 mo)
Silva et al[16]2010Cohort13MPA: 13MPO: 13181/13 – 7.7%
Hiemstra et al[14]2010Randomized156WG: 90; MPA: 56MPO: 51; PR3: 9039MYCOPHENOLATE GROUP 42/76 - 55% (18 major, 24 minor relapses); AZA 30/80 - 37.5% (10 major, 20 minor relapses)
Draibe et al[18]2015Case series20N/AMPO: 18N/A3/20 – 16% (time to relapse 18-23 mo)
Chen et al[17]2016Cohort31MPA: 31MPO: 31867/31 – 22.6% median time to relapse 43 mo (IQR 10-128 mo)